Skip to content
Screener

Simulations Plus SLP Clinical Operations — Revenue

Other product segments

Development
$17.07M+10.8%
Discovery
$2.48M-1.7%
Commercialization
$2.06M+1.8%

Similar metrics at other companies

WW International, Inc. logo
WWClinical Subscription Revenues — Revenue
$39.91M+38.3%
Tempus AI, Inc. logo
TEMClinical Order — Revenue
$239.3M+31.8%
SRT
SRTAOther Clinical — Revenue
$9.95M
SRT
SRTATransplant Clinical — Revenue
$9.84M
Maximus logo
MMSClinical Services — Revenue
$553.08M-1.3%
SRT
SRTAClinical — Revenue
$19.79M

Other financials

Income statement

See full
Revenue$21.9M+7.5%
Gross profit$15.1M+16.1%
Operating income$4.5M+106%
Net income$3.6M+105%
EPS (diluted)$0.18+105%

Balance sheet

See full
Cash & equivalents$35.3M+31.1%
Total debt$487.0K-32.3%
Total equity$139.0M+12.3%
Total assets$153.0M+13.9%

Cash flow

See full
Operating cash flow$8.7M+6.9%
CapEx$93.0K-68.7%
Free cash flow$8.6M+9.8%

Valuation

See full
Market cap$370.52M+32.9%
Enterprise value$335.68M+33.0%
P/E45.7×
P/S4.5×+1.0×

Profitability

See full
Gross margin63.4%+9.6pp
Operating margin13.2%
Net margin9.9%+5.2pp
FCF margin29.9%+12.8pp

Returns & leverage

See full
Return on equity6.2%+3.3pp
Debt / equity0.0×
Current ratio5.5×+0.4×

Where this comes from

Reported directly by Simulations Plus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Simulations Plus’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:10 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q2 2026
Accession
0001023459-26-000038
(in thousands)For the three months ended / May 31, 2026For the three months ended / % of total*For the three months ended / May 31, 2025For the three months ended / % of total
Discovery$2,48420%$2,52720%
Development9,81378%9,63177%
Clinical Operations2772%4163%
Commercialization3441
Total Software12,608100%12,615100%
Discovery
Development7,25578%5,76874%
Commercialization2,02322%1,98026%

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Simulations Plus's clinical operations — revenue?
Simulations Plus (SLP) reported clinical operations — revenue of $277K in Q1 2026.
How has Simulations Plus's clinical operations — revenue changed year-over-year?
Simulations Plus's clinical operations — revenue decreased by 33.4% year-over-year, from $416K to $277K.
What does clinical operations — revenue mean?
This metric represents the total gross revenue generated from clinical operations, consulting, and contract research services provided to the pharmaceutical and biotechnology industries. It tracks the financial performance of the service-based segment, reflecting the company's ability to monetize its expertise in drug development and clinical trial support. Monitoring this revenue stream helps investors assess the scale and growth trajectory of the company's service-oriented business model.

Ask your AI about Simulations Plus's clinical operations — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude